Intellia Therapeutics Inc header image

Intellia Therapeutics Inc

NTLA

Equity

ISIN null / Valor 32256913

NASDAQ (2026-05-27)
USD 13.44+6.58%

Intellia Therapeutics Inc
UMushroom community rating:

star star star star star
4.00 2 votes No rating yet
NegativeNeutralPositive

About company

Intellia Therapeutics Inc is a biotechnology company focused on developing curative genome editing treatments using CRISPR/Cas9 technology. Founded with the mission to transform the lives of people with severe diseases, Intellia collaborates with partners like Regeneron to explore in vivo applications of genome editing. The company's work in harnessing the potential of CRISPR to make specific changes in the DNA of humans, animals, and plants has captured global attention for its potential to revolutionize disease treatment. Led by co-founder Jennifer Doudna, Intellia is at the forefront of the genome editing field, working towards developing innovative therapies for a range of genetic disorders.

Summarized from source with an LLMView SourceSector: Technology

Latest Results ():

Summarized from source with an LLMView Source

Key figures

44.1%1Y
-65.5%3Y
-81.3%5Y

Performance

105%1Y
80.3%3Y
80.9%5Y

Volatility

Market cap

1878 M

Market cap (USD)

Daily traded volume (Shares)

6,548,662

Daily traded volume (Shares)

1 day high/low

11.8 / 11.355

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

4.00

2 votes
Performance:
starstarstarstarstar
3.00
Innovation:
starstarstarstarstar
4.50
Society:
starstarstarstarstar
3.00
Nature:
starstarstarstarstar
2.50
Fabio Kull
Switzerland, 18 Oct 2025
star star star star star
They use CRISPR technology to edit DNA inside the body. High potential.
Samuel Hitracek
Switzerland, 17 Oct 2025
star star star star star
Intersting

EQUITIES OF THE SAME SECTOR

Bread Financial Holdings Inc
Bread Financial Holdings Inc Bread Financial Holdings Inc Valor: 1048752
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.59%USD 89.92
Flex Ltd
Flex Ltd Flex Ltd Valor: 188067
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.78%USD 145.79
Alkami Technology Inc
Alkami Technology Inc Alkami Technology Inc Valor: 110527431
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.00%USD 16.80
Ziff Davis Inc
Ziff Davis Inc Ziff Davis Inc Valor: 14502324
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.17%USD 45.73
Hexaware Technologies Limited
Hexaware Technologies Limited Hexaware Technologies Limited Valor: 141889544
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.10%INR 508.40
Charles River Laboratories International Inc
Charles River Laboratories International Inc Charles River Laboratories International Inc Valor: 1097832
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
4.95%USD 164.49
Avery Dennison Corp
Avery Dennison Corp Avery Dennison Corp Valor: 910162
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.45%USD 160.52
Grifols, SA
Grifols, SA Grifols, SA Valor: 30689500
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.15%EUR 7.01
Nordic Semiconductor ASA
Nordic Semiconductor ASA Nordic Semiconductor ASA Valor: 440145
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.75%NOK 201.60
Flywire Corp
Flywire Corp Flywire Corp Valor: 111444572
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.19%USD 15.81